Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aus-131. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 known ✓ | Q92731 | 7/20 | 1.00 |
| ▸ | ESR1 | P03372 | 6/20 | 1.00 |
| ▸ | TTR | P02766 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 7/20 | 0.74 |
| ▸ | ALOX12 | P18054 | 6/20 | 0.74 |
| ▸ | ALOX15B | O15296 | 3/20 | 0.74 |
| ▸ | RARA | P10276 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 1/20 | 0.45 |
| ▸ | RARG | P13631 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aus-131 SCHEMBL677723 | 1.00 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL29467332 | 1.00 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL43647 | 1.00 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL43648 | 1.00 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL17591903 | 0.91 | ESR2 (0.83) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL31545730 | 0.91 | ESR2 (0.83) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL19861143 | 0.91 | ESR2 (0.83) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL17679253 | 0.91 | ESR2 (0.83) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL30720187 | 0.90 | ESR2 (0.82) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL4360255 | 0.90 | ESR2 (0.82) | ESR2ESR1TTRALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4679087-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| EP-4679086-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| CN-118947703-A | Application of equol in inhibiting plant pathogenic bacteria | 中国农业科学院烟草研究所(中国烟草总公司青州烟草研究所) | 2024-11-15 | — | — | CN | claimed |
| WO-2024190663-A1 | BIOMARKER AND USE THEREOF | 株式会社明治 | 2024-09-19 | — | — | WO | claimed |
| US-12070443-B2 | Methods of treating and preventing breast cancer with S-equol | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-08-27 | — | — | US | claimed |
| US-12070444-B2 | Modulation of molecular markers using S-equol | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-08-27 | — | — | US | claimed |
| US-12064413-B2 | Methods of treating melanoma with S-equol | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-08-20 | — | — | US | claimed |
| CN-117065038-A | Carrier for anticancer drug (R) -equol and preparation method and application thereof | 上海工程技术大学 | 2023-11-17 | — | — | CN | claimed |
| EP-4251281-A1 | MODULATION OF MOLECULAR MARKERS USING S-EQUOL | Li, Rong (US) | 2023-10-04 | — | — | EP | claimed |
| CN-110622002-B | Anti-equol antibody composition and use thereof | 株式会社乐检生物科技 | 2023-04-07 | — | — | CN | claimed |
| US-20220387380-A1 | METHODS OF TREATING AND PREVENTING MELANOMA WITH S-EQUOL | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-12-08 | — | — | US | claimed |
| WO-2022115582-A9 | MODULATION OF MOLECULAR MARKERS USING S-EQUOL | LI RONG (US) | 2022-08-18 | — | — | WO | claimed |
| CN-112763606-B | Quality analysis method of aconite root middle-jiao regulating preparation differential compound | 成都中医药大学 | 2022-07-08 | — | — | CN | claimed |
| WO-2022115582-A1 | MODULATION OF MOLECULAR MARKERS USING S-EQUOL | LI RONG (US) | 2022-06-02 | — | — | WO | claimed |
| US-20220160678-A1 | MODULATION OF MOLECULAR MARKERS USING S-EQUOL | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-26 | — | — | US | claimed |
| EP-4679086-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | disclosed |
| EP-4679087-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | disclosed |
| EP-1919887-A2 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | Girindus America, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007016423-A2 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | AUSIO PHARMACEUTICALS, LLC | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160678-A1 | MODULATION OF MOLECULAR MARKERS USING S-EQUOL | BRCA1, ESRRG, ESR1 | ESR2 4/4885ESR1 3/4885TTR 4347/4885 |
| US-20220387380-A1 | METHODS OF TREATING AND PREVENTING MELANOMA WITH S-EQUOL | EGLN2, ELF3, EGLN3 | ESR2 82/4885ESR1 361/4885TTR 4249/4885 |
| US-12070444-B2 | Modulation of molecular markers using S-equol | BRCA1, ESRRG, ESR1 | ESR2 4/4885ESR1 3/4885TTR 4347/4885 |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | HRH3, HRH2, CHD8 | ESR2 7/4885ESR1 11/4885TTR 4208/4885 |
| US-12064413-B2 | Methods of treating melanoma with S-equol | EGLN2, ELF3, ESYT2 | ESR2 77/4885ESR1 408/4885TTR 4386/4885 |
| US-12070443-B2 | Methods of treating and preventing breast cancer with S-equol | BRCA1, ESR1, ESR2 | ESR2 3/4885ESR1 2/4885TTR 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.